Alcon

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company focused on the identification, development, and commercialization of innovative ophthalmic therapies. The company aims to address significant unmet medical needs in the ophthalmology sector within China by offering a comprehensive pharmaceutical solution. Ocumension Therapeutics has established a robust platform that integrates specialized capabilities across the entire development cycle of ophthalmic drugs, including research and development, manufacturing, and commercialization. Its diverse portfolio of product candidates features several treatments such as OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), and OT-1001 (ZERVIATE), among others. By leveraging its first-mover advantage and specialized expertise, Ocumension Therapeutics aspires to become a leader in the Chinese ophthalmology market.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

EYSUVIS Portfolio of dry eye disease therapies and medications designed to make ocular surgery easier.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

TrueVision Systems is a company focused on enhancing surgical and educational practices through advanced 3D, high-definition digital imaging technology. It specializes in the development of the TrueVision 3DHD vision system, which is designed to improve visualization during microsurgery, thereby facilitating better patient outcomes and surgical efficiencies. Founded by Dr. Michael Weissman, a leading expert in digital stereoscopic imaging, TrueVision aims to address the limitations of traditional surgical microscopes. The company employs a team of experienced professionals, including veterans from notable medical imaging firms, and its senior technical staff features several PhDs in relevant fields. In addition to manufacturing its proprietary vision system, TrueVision licenses its technology for various stereoscopic visualization applications across medical and non-medical sectors. The integration of robotics, precise visualization, and real-time patient data further enhances the system's efficacy, contributing to improved surgical accuracy and efficiency.

Tear Film Innovations Inc. is a San Diego-based company founded in 2014 that specializes in developing medical devices for the treatment of evaporative dry eye and related conditions, such as meibomian gland dysfunction and blepharitis. The company’s flagship product, the iLux Dry Eye Treatment System, is an FDA-cleared handheld device that allows eye care professionals to quickly evaluate and treat patients suffering from dry eye within ten minutes. This innovative system focuses on addressing blocked meibomian glands through targeted heating and compression, enhancing the efficiency of meibomian gland dysfunction treatment. As a subsidiary of Alcon, Inc., Tear Film Innovations aims to improve patient outcomes for the millions affected by evaporative dry eye worldwide.

Transcend Medical, Inc. is an ophthalmic device company based in Menlo Park, California, focused on developing innovative medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005, Transcend Medical emerged from ForSight Labs, an incubator dedicated to ophthalmic innovations. The company's flagship product, the CyPass Micro-Stent, is a micro-invasive device designed to be implanted during routine cataract surgery to reduce intraocular pressure. Additionally, Transcend Medical offers the Vold Gonio Lens for use in micro-invasive glaucoma surgeries and provides clinical trial services. The CyPass Micro-Stent received its CE mark in 2008 and has been undergoing evaluation in various clinical studies, including the COMPASS multi-center trial, to assess its effectiveness and safety in treating glaucoma. As of 2016, Transcend Medical operates as a subsidiary of Alcon Holdings, Inc.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

SensoMotoric Instruments GmbH is a leading developer and marketer of application-specific gaze and eye tracking systems, original equipment manufacturer solutions, and medical applications. Established in 1991 and headquartered in Teltow, Germany, with additional offices in Berlin and Boston, the company offers a range of products tailored for various sectors, including market research, neuromarketing, neuroscience, ophthalmology, and education. Their offerings include eye tracking platforms for desktop and mobile devices, wearable eye tracking glasses, and solutions for virtual and augmented reality applications. SensoMotoric Instruments serves a global customer base and is recognized for its innovative products and services, with over 6,000 eye tracker systems operational worldwide.

LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

Wavelight designs, manufactures, and markets advanced laser systems for various medical, aesthetic, and industrial applications. The company specializes in ophthalmology, dermatology, and urology, offering innovative solutions that enhance the precision and effectiveness of medical procedures. Wavelight's product portfolio includes advanced diagnostic and surgical technologies aimed at correcting vision defects, such as electronic guidance systems for positioning intraocular lenses and eye-tracking systems for laser treatments. These technologies enable healthcare professionals to achieve greater accuracy and reproducibility in refractive cataract surgeries, thereby improving patient outcomes.